New drug combo aims to shrink lung tumors before surgery
NCT ID NCT06918132
First seen Dec 16, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase II trial is testing whether giving a combination of two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more tumor cells in people with stage IB to IIIB non-small cell lung cancer. About 60 participants will receive the drugs intravenously, then undergo surgery to remove their cancer. The main goal is to see how many patients have a major pathologic response, meaning 10% or fewer viable tumor cells remain after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab and fianlimab (immunotherapy drugs)
What this could lead to
If it works, this could offer a chemotherapy-free option before lung cancer surgery, potentially improving outcomes for patients with certain PD-L1 levels.
What could go wrong
This is a small, early-phase trial (60 participants) with no control group. The drugs may cause immune-related side effects, and results may not apply to all lung cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.